Oxford’s adoption of Olink tech to ‘unravel mechanisms of disease’ – The Pharma Letter

Swedens Olink Holding (Nasdaq: OLK) has announced that Oxford Genomics at the University of Oxford is adopting its technology, becoming the UKs first Olink lab.

It is hoped that the partnership will enable new techniques to unravel mechanisms of disease using the Olink Explore platform.

"We are trying to make the drug development process more precise by understanding the heterogeneity in the patients instead of one drug fits all"According

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Visit link:
Oxford's adoption of Olink tech to 'unravel mechanisms of disease' - The Pharma Letter